Key result
This review provides an update on laboratory guidance and the progress of methods for measuring the pharmacodynamics and pharmacokinetics of direct oral anticoagulants.
Why the study?
There is an increasing demand for laboratory capacity to assess DOAC anticoagulant effects or levels in emergent or routine situations, despite these drugs not being routinely monitored like coumadin.
This review provides updated guidance on the laboratory assessment and methods for measuring the pharmacodynamics and pharmacokinetics of direct oral anticoagulants.
May guide DOAC laboratory assessment; leaves open prospective validation of new methods.
The first direct oral anticoagulant (DOAC) to be approved for clinical use was dabigatran, a direct thrombin inhibitor, in 2010. Since that time, four additional DOACs, all direct anti-Xa inhibitors, have been approved, including rivaroxaban, apixaban, edoxaban and betrixaban. Our knowledge about the effect of DOACs on laboratory testing, as well as the use of the laboratory for measuring DOACs has been an evolving process. These drugs are not routinely monitored in the same fashion as coumadin, but there is an increasing demand on the laboratory to have the capacity to adequately assess DOAC anticoagulant effect (pharmacodynamics) or levels (pharmacokinetics) in either emergent or the routine situations. This manuscript provides an update on laboratory guidance and progress of methods for measuring DOACs.
No takes yet. Share an insight, caveat, or question.
Gosselin et al. (2019) conducted a review in Direct oral anticoagulants (DOACs) laboratory assessment. Direct oral anticoagulants (DOACs) was evaluated. This review provides an update on laboratory guidance and the progress of methods for measuring the pharmacodynamics and pharmacokinetics of direct oral anticoagulants.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: